Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
- PMID: 34763002
- DOI: 10.1016/j.addr.2021.114041
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
Abstract
RNA therapeutics (e.g. siRNA, oligonucleotides, mRNA, etc.) show great potential for the treatment of a myriad of diseases. However, to reach their site of action in the cytosol or nucleus of target cells, multiple intra- and extracellular barriers have to be surmounted. Several non-viral delivery systems, such as nanoparticles and conjugates, have been successfully developed to meet this requirement. Unfortunately, despite these clear advances, state-of-the-art delivery agents still suffer from relatively low intracellular delivery efficiencies. Notably, our current understanding of the intracellular delivery process is largely oversimplified. Gaining mechanistic insight into how RNA formulations are processed by cells will fuel rational design of the next generation of delivery carriers. In addition, identifying which intracellular pathways contribute to productive RNA delivery could provide opportunities to boost the delivery performance of existing nanoformulations. In this review, we discuss both established as well as emerging techniques that can be used to assess the impact of different intracellular barriers on RNA transfection performance. Next, we highlight how several modulators, including small molecules but also genetic perturbation technologies, can boost RNA delivery by intervening at differing stages of the intracellular delivery process, such as cellular uptake, intracellular trafficking, endosomal escape, autophagy and exocytosis.
Keywords: Cellular delivery; Cellular uptake; Conjugates; Endosomal escape; Intracellular barriers; Intracellular trafficking; Nanoparticles; Nucleic acid therapeutics.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies.Adv Drug Deliv Rev. 2021 Dec;179:113999. doi: 10.1016/j.addr.2021.113999. Epub 2021 Oct 27. Adv Drug Deliv Rev. 2021. PMID: 34715258 Free PMC article. Review.
-
RNAi-based therapeutics and tumor targeted delivery in cancer.Adv Drug Deliv Rev. 2022 Mar;182:114113. doi: 10.1016/j.addr.2022.114113. Epub 2022 Jan 19. Adv Drug Deliv Rev. 2022. PMID: 35063535 Review.
-
Lipid nanoparticles for short interfering RNA delivery.Adv Genet. 2014;88:71-110. doi: 10.1016/B978-0-12-800148-6.00004-3. Adv Genet. 2014. PMID: 25409604 Free PMC article. Review.
-
Current issues of RNAi therapeutics delivery and development.J Control Release. 2014 Dec 10;195:49-54. doi: 10.1016/j.jconrel.2014.07.056. Epub 2014 Aug 9. J Control Release. 2014. PMID: 25111131 Review.
-
Non-viral Delivery of Nucleic Acids: Insight Into Mechanisms of Overcoming Intracellular Barriers.Front Pharmacol. 2018 Aug 21;9:971. doi: 10.3389/fphar.2018.00971. eCollection 2018. Front Pharmacol. 2018. PMID: 30186185 Free PMC article. Review.
Cited by
-
Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applications.Mol Ther Nucleic Acids. 2024 Aug 19;35(3):102313. doi: 10.1016/j.omtn.2024.102313. eCollection 2024 Sep 10. Mol Ther Nucleic Acids. 2024. PMID: 39281702 Free PMC article. Review.
-
Epigenetics-targeted drugs: current paradigms and future challenges.Signal Transduct Target Ther. 2024 Nov 26;9(1):332. doi: 10.1038/s41392-024-02039-0. Signal Transduct Target Ther. 2024. PMID: 39592582 Free PMC article. Review.
-
Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy.Mol Cancer. 2022 Mar 11;21(1):71. doi: 10.1186/s12943-022-01550-8. Mol Cancer. 2022. PMID: 35277177 Free PMC article. Review.
-
Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV.Mol Ther Nucleic Acids. 2025 May 20;36(3):102572. doi: 10.1016/j.omtn.2025.102572. eCollection 2025 Sep 9. Mol Ther Nucleic Acids. 2025. PMID: 40529300 Free PMC article. Review.
-
Recent Advances in Nanomaterials for Modulation of Stem Cell Differentiation and Its Therapeutic Applications.Biosensors (Basel). 2024 Aug 22;14(8):407. doi: 10.3390/bios14080407. Biosensors (Basel). 2024. PMID: 39194636 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources